Cancer & Disease Research Sponsored by Beckman Coulter
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14.  Discuss
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic.  Discuss
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11.  Discuss
Gum disease may affect COVID-19 severity
Patients with inflammation caused by periodontitis may experience more severe COVID-19 complications, according to an article published online July 30 in the Journal of the California Dental Association.  Discuss
New tools rapidly detect anti-SARS-CoV-2 antibodies
New tools using surrogate viruses may be useful for rapid testing to determine whether antibodies effectively neutralize SARS-CoV-2. The viral vector-based platform approach was published in the Journal of Experimental Medicine on July 21.  Discuss
NIH forms COVID-19 clinical trials network
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has established a new clinical trials network to conduct large-scale testing of COVID-19 vaccines and monoclonal antibodies.  Discuss
High-throughput analysis speeds downstream process development
Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case study presented June 17 during the BioProcess International Spring Digital Week 2020.  Discuss
Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher from GlaxoSmithKline discussed how her team uses an optofluidic system in a June 15 presentation at the BioProcess International Spring Digital Week's 2020 virtual meeting.  Discuss
New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published in Nature Biotechnology on May 18, may change the drug discovery process by moving beyond reliance on chemical information alone.  Discuss
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines, according to a new study. The findings were published in Nature on May 18.  Discuss
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter